T1	Participants 0 87	Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients
T2	Participants 230 241	hot flashes
T3	Participants 143 218	Breast cancer patients with treatment-induced menopause experience frequent
T4	Participants 260 388	venlafaxine and clonidine for the treatment of HF with regard to side effects, efficacy, quality of life and sexual functioning.
T5	Participants 434 580	60 breast cancer patients experiencing HF were randomized to 8 weeks venlafaxine followed by 2 weeks wash-out, and 8 weeks clonidine or vice versa
T6	Participants 676 738	Thirty patients started with venlafaxine and 30 with clonidine
T7	Participants 609 666	side effects, quality of life and sexuality were assessed
T8	Participants 913 967	HF score was 49% for venlafaxine and 55% for clonidine
T9	Participants 985 1064	Venlafaxine and clonidine are equally, but moderately effective in HF reduction
T10	Participants 1066 1162	Side effects are the main reason for drug discontinuation, occurring more often with venlafaxine
